ETNB - 89bio announces additional early stage data for NASH therapy

89bio ([[ETNB]] +4.4%) has revealed the additional data from its Phase 1b/2a study of BIO89-100 in patients with nonalcoholic steatohepatitis (“NASH”).The results to be presented in a poster presentation at the ongoing Endocrine Society’s annual meeting indicates that BIO89-100 at 13 weeks has led to reductions in the liver volume of up to 15% and liver fat volume of up to 65% in patients compared to baseline.The data as measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) contrasts with previously reported MRI-PDFF data which showed a 70% relative reduction in liver fat fraction relative to placebo treatment.As previously reported, with a favorable safety and tolerability profile, the experimental treatment has caused gastrointestinal side effects such as nausea, diarrhea, and vomiting similar to placebo.In January, announcing its plans on BIO89-100, 89bio said that it expected to initiate the Phase 2b NASH trial in H1 2021 with top-line Phase 2 data

For further details see:

89bio announces additional early stage data for NASH therapy